<?xml version="1.0" encoding="UTF-8"?>
<p>As shown in 
 <xref rid="pathogens-08-00176-t003" ref-type="table">Table 3</xref>, reports regarding DAA-based regimens for HCV-related glomerular disease are limited [
 <xref rid="B21-pathogens-08-00176" ref-type="bibr">21</xref>,
 <xref rid="B22-pathogens-08-00176" ref-type="bibr">22</xref>,
 <xref rid="B23-pathogens-08-00176" ref-type="bibr">23</xref>,
 <xref rid="B24-pathogens-08-00176" ref-type="bibr">24</xref>,
 <xref rid="B25-pathogens-08-00176" ref-type="bibr">25</xref>,
 <xref rid="B26-pathogens-08-00176" ref-type="bibr">26</xref>,
 <xref rid="B27-pathogens-08-00176" ref-type="bibr">27</xref>,
 <xref rid="B28-pathogens-08-00176" ref-type="bibr">28</xref>,
 <xref rid="B29-pathogens-08-00176" ref-type="bibr">29</xref>]. Collectively, the frequency of SVR was 92% (62/67). The rate of complete clinical response after DAAs was 32.8% (22/67). A number of patients required immunosuppression while on therapy with DAAs (
 <italic>n </italic>= 29, 43%). Some patients received immunosuppression after antiviral therapy ended [
 <xref rid="B28-pathogens-08-00176" ref-type="bibr">28</xref>].
</p>
